18
Jun
2025
Actio Bio, Running Fast and Lean, Pockets $66M for Precision Neuro Drug R&D
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
17
Jun
2025
From Optimization to Agency: Reframing the Future of Personal Health
While medical advances have afforded us the luxury of longer lives, we now spend many of our later years coping with the ravages of chronic illnesses of aging — cardiovascular disease, type 2 diabetes, neurodegenerative conditions like Alzheimer’s, and cancer. Many of these conditions seem linked to long-term exposure to low grade systemic inflammation, a pathological process known as “inflammaging.” ... Read More
12
Jun
2025
Avidity Advances in FSHD, Insmed Passes PAH Test, Merck Delivers with Oral PCSK9
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
11
Jun
2025
Finding Therapies in Long Non-Coding RNA: John Rinn on The Long Run
John Rinn is today’s guest on The Long Run. John is the Leslie Orgel and Marvin Caruthers professor of RNA science at the University of Colorado in Boulder. His research is focused on long non-coding RNAs. This is the vast expanse of the genome that doesn’t contain genes with code for making proteins. Researchers once dismissed this area of the... Read More
5
Jun
2025
Sanofi Buys Blueprint, BMS Antes for BioNTech Bispecific, & Kymera Degrader Delivers
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
Jun
2025
Request an Invitation to the Timmerman Traverse
Timmerman Traverse is looking for a few good men and women. Opportunities are here for people who are physically fit, enjoy nature, thrive in community, and who want to roll up the sleeves for worthy causes — including cancer research, sickle cell disease and fighting poverty. Here’s how to get involved. Timmerman Traverse for Life Science Cares This 2-day expedition... Read More
3
Jun
2025
NEJM Study Linking Exercise, Cancer Recovery Raises Two Concerns: What If It’s Wrong? What If It’s Right?
This week featured a rare crossing of the streams, as the buttoned-down world of cancer research met the buzzy world of exercise and wellness. One result: a randomized controlled study of exercise in 889 cancer patients published in the New England Journal of Medicine (NEJM), and accompanied by a torrent of enthusiastic coverage in the popular press. Another: the publication... Read More
29
May
2025
GSK Antibiotic Hits, ORIC Prostate Cancer Drug Shines, & Taysha Goes 10-for-10
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
May
2025
5 East Asian Americans in Biopharma on Pivotal Moments in Their Immigration Story
They called it Gold Mountain. For Chinese in the 19th century, the “gold mountains” of California and North America represented the promise of success and upward mobility. It was their name for the American Dream. And at a time when America’s appeal to dreamers and strivers around the world is under strain, it’s worthwhile to reflect on the incredible paths... Read More
28
May
2025
A New and Old Idea for Cardiovascular Disease & Diabetes: Ethan Weiss & Josh Lehrer on The Long Run
Ethan Weiss and Josh Lehrer are today’s guests on The Long Run. Ethan is the co-founder and chief scientific officer of South San Francisco-based Marea Biosciences. Josh is the CEO. They are seeking to blaze a new trail with a drug to reduce the risk of cardiovascular disease and type 2 diabetes. It’s a monoclonal antibody aimed at ANGPTL4. There... Read More
27
May
2025
GlycoEra Grabs $130M to Develop Extracellular Degraders for Autoimmunity
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
27
May
2025
Reclaiming Biotech’s Edge: In Defense of Taking Disciplined Risk
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
22
May
2025
Vigil, Inozyme Acquired, Prime Cuts, & Regeneron Scoops Up 23andMe
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
May
2025
Genentech’s Bet on NC, GSK Buys Boston Liver Drug, & Septerna Entices Novo
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
13
May
2025
Biologic Drug Discovery Made Faster: Peyton Greenside on The Long Run
Peyton Greenside is today’s guest on The Long Run. Peyton is the co-founder and CEO of San Mateo, Calif.-based BigHat Biosciences. The company was started in 2019 to build on advances in synthetic biology and machine learning to design antibody drugs with a variety of different properties, faster. The company has gone on to raise more than $100 million in... Read More
8
May
2025
Health Deserves A Vision More Capacious Than Dashboard Metrics
Consumer health and wellness is experiencing a flurry of activity. The lab testing company Function (motto: “It’s time to own your health”) acquired Ezra, a whole body MRI company promising “the world’s most advanced longevity scan.” Oura, maker of the popular smart ring, recently added an integration for continuous glucose measurement as well as the ability to calculate meal... Read More
8
May
2025
NewLimit’s Anti-Aging Bounty, a Twist Spinout, & AI Coming to the FDA
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
4
May
2025
Tech-Enabled Power To The People: Ingratiating Chatbots and a Virtuous Food App
For at least a decade, nearly every tech company has promoted their product as facilitating the “democratization” of something – perhaps “data driven medicine,” or “genetic information” or “access to clinical trials” or “digital health” (all real examples). Like “mission-driven,” “results-oriented,” and “disruptive,” the term “democratization” has become so overused by the tech community that it’s now more of an... Read More
3
May
2025
Our Collective Hope For AI in Health, Plus Explanatory Models and an Epic Podcast
A recent piece by Nathan Price captures our collective hope for AI in health with unusual clarity, even as there remains impassioned disagreement regarding how close these ambitions are to meaningful realization. For context, Price is Professor and Co-Director of the Center for Human Healthspan at the Buck Institute for Research on Aging and CSO of Thorne, a company best... Read More
2
May
2025
A Sublime Experience: Views of Timmerman Traverse for Damon Runyon Cancer Research
Kathmandu, Nepal We did it together. The Timmerman Traverse for Damon Runyon Cancer Research Foundation completed a splendid expedition to Everest Base Camp on Apr. 23, 2025. This trip succeeded on every count. All 17 members of the team made it to the mountaineering camp at 17,600 feet / 5,364 meters. We exceeded our $700,000 fundraising goal for high-risk /... Read More